Clal Biotechnology Industries 관리

Dr. Avraham Matityahu Fischer, also known as Avi, M.D., is Co-Managing Partner of Fischer Behar Chen Well Orion & Co. Dr. Fischer is Deputy CEO, Executive VP and Deputy Chairman of Idb Development Corporat...

리더십 팀

이름	위치	테뉴어	보상	소유권
Avraham Fischer	Chairman & CEO	less than a year	₪586.00k	데이터 없음
Liat Nissan	Chief Financial Officer	2.1yrs	₪975.00k	데이터 없음
Iris Sadeh	Accountant	2.8yrs	데이터 없음	데이터 없음
Shiran Manor	General Counsel & Corporate Secretary	no data	데이터 없음	데이터 없음
Etty Kliger	Vice President of Research & Development - MediWound	no data	₪1.10m	데이터 없음
Lior Rosenberg	Vice President of Medical Technologies - MediWound	no data	₪1.21m	데이터 없음
Arnon Aharon	Medical Director	2.8yrs	데이터 없음	데이터 없음

2.5yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 관리: CBI 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Avraham Fischer	Chairman & CEO	21.5yrs	₪586.00k	데이터 없음
Yuval Yanai	External Independent Director	8.9yrs	데이터 없음	데이터 없음
Gonen Bieber	Director	less than a year	데이터 없음	데이터 없음
Gad Keren	Independent External Director	4.8yrs	데이터 없음	데이터 없음
Gabriel Barabash	Director	21.7yrs	데이터 없음	데이터 없음
Nufar Malovani	Director	7yrs	데이터 없음	데이터 없음
Tomer Babai	Director	6.9yrs	데이터 없음	데이터 없음

7.0yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: CBI 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Clal Biotechnology Industries 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Clal Biotechnology Industries (TLV:CBI) Is Carrying A Fair Bit Of Debt

New major risk - Financial position

Clal Biotechnology Industries Ltd., Annual General Meeting, May 06, 2024

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Share price stability

The Market Doesn't Like What It Sees From Clal Biotechnology Industries Ltd.'s (TLV:CBI) Revenues Yet

Third quarter 2022 earnings released: ₪0.015 loss per share (vs ₪0.12 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings released: ₪0.22 loss per share (vs ₪0.22 loss in 2Q 2021)

Calculating The Fair Value Of Clal Biotechnology Industries Ltd. (TLV:CBI)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Does Clal Biotechnology Industries (TLV:CBI) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investors Shouldn't Be Too Comfortable With Clal Biotechnology Industries' (TLV:CBI) Robust Earnings

Clal Biotechnology Industries (TLV:CBI) Seems To Use Debt Quite Sensibly

Full year 2020 earnings released: EPS ₪0.68 (vs ₪0.96 loss in FY 2019)

ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

New 90-day low: ₪1.75

Introducing Clal Biotechnology Industries (TLV:CBI), The Stock That Zoomed 121% In The Last Year

New 90-day high: ₪2.24

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day high: ₪2.23

What Kind Of Shareholders Own Clal Biotechnology Industries Ltd. (TLV:CBI)?

Novartis AG (SWX:NOVN) reached a definitive agreement to acquire Cadent Therapeutics, Inc. from a group of sellers for approximately $770 million.

ChemomAb Ltd. entered into a definitive merger agreement to acquire Anchiano Therapeutics Ltd. (NasdaqCM:ANCN) in a reverse merger transaction.

Is Clal Biotechnology Industries (TLV:CBI) Using Too Much Debt?

New 90-day low: ₪1.58

New 90-day high: ₪1.87

New 90-day high - ₪1.76

BioNTech SE (NasdaqGS:BNTX) completed the acquisition of Neon Therapeutics, Inc. (NasdaqGS:NTGN) from Third Rock Ventures, LLC and others.

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령